|
36.
|
|
|
37.
|
|
10 p, 964.3 KB |
Guideline on the use of onabotulinumtoxinA in chronic migraine : a consensus statement from the European Headache Federation
/
Bendtsen, Lars (University of Copenhagen) ;
Sacco, Simona (University of L'Aquila. Neuroscience Section, Department of Applied Clinical Sciences and Biotechnology) ;
Ashina, Messoud (University of Copenhagen) ;
Mitsikostas, Dimos (National and Kapodistrian University of Athens. 1st Department of Neurology, Aeginition Hospital) ;
Ahmed, Fayyaz (Hull York Medical School. Department of Neurosciences) ;
Pozo-Rosich, Patricia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Martelletti, Paolo (Sapienza University. Department of Clinical and Molecular Medicine) ;
Universitat Autònoma de Barcelona ;
Hospital Universitari Vall d'Hebron
OnabotulinumtoxinA is being increasingly used in the management of chronic migraine (CM). Treatment with onabotulinumtoxinA poses challenges compared with traditional therapy with orally administered preventatives. [...]
2018 -  10.1186/s10194-018-0921-8
Journal of headache and pain, Vol. 19 (september 2018)
|
|
|
38.
|
|
13 p, 823.6 KB |
Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine : The multicentre, double-blind, randomised, sham-controlled PREMIUM trial
/
Diener, Hans-Christoph (University Duisburg-Essen) ;
Goadsby, Peter J. (King's College London) ;
Ashina, Messoud (Glostrup University Hospital Copenhagen) ;
Al-Karagholi, Mohammad Al-Mahdi (Glostrup University Hospital Copenhagen) ;
Sinclair, Alexandra J. (Metabolic Neurology, Institute of Metabolism and Systems Research, University of Birmingham) ;
Mitsikostas, Dimos (1st National and Kapodistrian University of Athens) ;
Magis, Delphine (CHR East Belgium) ;
Pozo-Rosich, Patricia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Irimia Sieira, Pablo (Clínica Universidad de Navarra) ;
Làinez, Miguel J. A. (Universidad Católica de Valencia) ;
Gaul, Charly (Migraine and Headache Clinic) ;
Silver, Nicholas (The Walton Centre) ;
Hoffmann, Jan (King's College London) ;
Marin, Juana (King's College London) ;
Liebler, Eric (electroCore, Inc., Basking Ridge) ;
Ferrari, Michel D.. (Leiden University Medical Center) ;
Universitat Autònoma de Barcelona
Non-invasive vagus nerve stimulation (nVNS; gammaCore®) has the potential to prevent migraine days in patients with migraine on the basis of mechanistic rationale and pilot clinical data. This multicentre study included a 4-week run-in period, a 12-week double-blind period of randomised treatment with nVNS or sham, and a 24-week open-label period of nVNS. [...]
2019 - 10.1177/0333102419876920
Cephalalgia, Vol. 39 (september 2019) , p. 1475-1487
|
|
|
39.
|
|
9 p, 601.3 KB |
Quality assurance in specialized headache units in Spain : an observational prospective study
/
Pozo-Rosich, Patricia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Martínez-García, Alba (Miguel Hernández University. Calitè Research Group) ;
Pascual Gómez, Julio (Instituto de Investigación Sanitaria Valdecilla (Santander, Cantàbria)) ;
Ignacio, Emilio (Cádiz University) ;
Guerrero-Peral, Ángel L. (Instituto de Investigación Biomédica de Salamanca) ;
Balseiro-Gómez, José (Hospital Universitario de Getafe (Madrid)) ;
Porta-Etessam, Jesús (Hospital Clínico San Carlos (Madrid)) ;
Latorre-González, Germán (Hospital Universitario de Fuenlabrada ( Madrid)) ;
Layos-Romero, Almudena (Complejo Hospitalario Universitario de Albacete) ;
Lucas, César (Hospital Universitario Virgen de la Arrixaca (Múrcia)) ;
Mira, José J. (Health Services Research in Chronic Illnesses Network)
To assess the quality of the therapeutic approach in Specialized Headache Units in Spain. An observational (prospective) study was conducted. Anonymized data of 313 consecutive patients during a defined period of time were analyzed and a comparison of performance in 13 consensual quality indicators between Specialized Headache Units and neurology consultations was calculated. [...]
2019 - 10.1186/s10194-019-1020-1
Journal of headache and pain, Vol. 20 (june 2019)
|
|
|
40.
|
|
|
41.
|
|
24 p, 365.1 KB |
Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults : Fourth edition
/
Diener, Hans-Christoph (University Hospital Essen (Alemanya)) ;
Tassorelli, Cristina (University of Pavia) ;
Dodick, David W. (Mayo Clinic) ;
Silberstein, Stephen D. (Thomas Jefferson University) ;
Lipton, Richard B. (Albert Einstein College of Medicine) ;
Ashina, Messoud (University of Copenhagen) ;
Becker, Werner J. (University of Calgary) ;
Ferrari, Michel D.. (Leiden University Medical Center) ;
Goadsby, Peter J. (King's College London) ;
Pozo-Rosich, Patricia (Hospital Universitari Vall d'Hebron) ;
Wang, Shuu-Jiun (National Yang-Ming University) ;
Mandrekar, Jay (Mayo Clinic Rochester) ;
Universitat Autònoma de Barcelona
The quality of clinical trials is an essential part of the evidence base for the treatment of headache disorders. In 1991, the International Headache Society Clinical Trials Standing Committee developed and published the first edition of the Guidelines for controlled trials of drugs in migraine. [...]
2019 - 10.1177/0333102419828967
Cephalalgia, Vol. 39 (february 2019) , p. 687-710
|
|
|
42.
|
|
13 p, 267.6 KB |
Issues Impacting Adverse Event Frequency and Severity : Differences Between Randomized Phase 2 and Phase 3 Clinical Trials for Lasmiditan
/
Kudrow, David (California Medical Clinic for Headache) ;
Krege, John H. (Eli Lilly and Company, Indianapolis) ;
Hundemer, Hans P. (Eli Lilly and Company, Bad Homburg) ;
Berg, Paul H. (Eli Lilly and Company, Indianapolis) ;
Khanna, Rashna (Eli Lilly and Company, Erl Wood) ;
Ossipov, Michael H. (Syneos Health, Clinical Division) ;
Pozo-Rosich, Patricia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Universitat Autònoma de Barcelona
We explore factors that may have contributed to differences in treatment-emergent adverse events in the phase 2 and phase 3 lasmiditan clinical trials. Phase 2 and phase 3 trials showed that the centrally penetrant 5-HT agonist, lasmiditan, was effective; higher frequency and severity of adverse events (AEs) were seen in phase 2. [...]
2020 - 10.1111/head.13731
Headache, Vol. 60 (january 2020) , p. 576-588
|
|
|
43.
|
|
10 p, 539.5 KB |
Evidence and experience with onabotulinumtoxinA in chronic migraine : Recommendations for daily clinical practice Evidencia y experiencia de bótox en migraña crónica: Recomendaciones para la práctica clínica diaria
/
Gago-Veiga, Ana Beatriz (Instituto de Investigación Hospital Universitario de la Princesa) ;
Santos Lasaosa, Sonia (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Cuadrado, María Luz (Universidad Complutense de Madrid. Departamento de Medicina) ;
Guerrero, Ángel Luis (Hospital Clínico Universitario de Valladolid) ;
Irimia, Pablo (Clínica Universidad de Navarra) ;
Lainez-Andres, J. M (Hospital Clínic Universitari (València)) ;
Leira, Rogelio (Hospital Clínico Universitario (Santiago de Compostela, Galícia)) ;
Pascual Gómez, Julio (Instituto de Investigación Sanitaria Valdecilla (Santander, Cantàbria)) ;
Sanchez del Río, Margarita (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ;
Viguera, Javier (Hospital Universitari Vall d'Hebron) ;
Pozo-Rosich, Patricia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Universitat Autònoma de Barcelona
OnabotulinumtoxinA has been demonstrated to be effective as a preventive treatment in patients with chronic migraine (CM). Five years after the approval of onabotulinumtoxinA in Spain, the Headache Study Group of the Spanish Society of Neurology considered it worthwhile to gather a group of experts in treating patients with CM in order to draw up, based on current evidence and our own experience, a series of guidelines aimed at facilitating the use of the drug in daily clinical practice. [...]
2019 - 10.1016/j.nrl.2017.09.008
Neurología, Vol. 34 Núm. 6 (julio 2019) , p. 408-417
|
|
|
44.
|
|
148 p, 2.6 MB |
Impacte de la migranya i factors relacionats
/
Torres-Ferrús, Marta ;
Pozo-Rosich, Patricia, dir. ;
Álvarez Sabín, José, dir. ;
Universitat Autònoma de Barcelona.
Departament de Medicina
L'objectiu d'aquesta tesis doctoral és millorar el coneixement de la discapacitat associada a la migranya i els factors que la condicionen per tal de mesurar l'impacte i poder desenvolupar eines que, a nivell clínic i poblacional, ens permetin quantificar millor la discapacitat. [...]
L'objectiu d'aquesta tesis doctoral és millorar el coneixement de la discapacitat associada a la migranya i els factors que la condicionen per tal de mesurar l'impacte i poder desenvolupar eines que, a nivell clínic i poblacional, ens permetin quantificar millor la discapacitat. [...]
The aim of this thesis is to improve the knowledge of the impact of migraine and its associated disability describing and evaluating the factors that influence it, in order to develop tools which will allow us to better measure it in the clinic and society. [...]
[Barcelona] : Universitat Autònoma de Barcelona, 2019.
|
|
|
45.
|
|
8 p, 843.7 KB |
The impact of onabotulinumtoxinA on severe headache days : PREEMPT 56-week pooled analysis
/
Matharu, Manjit (Queen Square, London, WC1N3BG UK) ;
Halker, Rashmi (East Mayo Blvd, Phoenix, AZ 85054 USA) ;
Pozo-Rosich, Patricia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
DeGryse, Ronald (Allergan plc, 2525 Dupont Dr, Irvine, CA USA) ;
Manack Adams, Aubrey (Allergan plc, 2525 Dupont Dr, Irvine, CA USA) ;
Aurora, Sheena K. (Pasteur Dr. Room A301 MC 5325, Stanford, CA USA) ;
Universitat Autònoma de Barcelona
OnabotulinumtoxinA has been shown to reduce headache-days among patients with chronic migraine (CM). The objective of this analysis was to determine whether onabotulinumtoxinA has an impact on headache-day severity in patients with CM among those patients who were deemed non-responders based on reduction in the frequency of headache days alone. [...]
2017 - 10.1186/s10194-017-0784-4
Journal of headache and pain, Vol. 18 (august 2017)
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
